MX9701333A - Metodos para inhibir el daño neuronal. - Google Patents
Metodos para inhibir el daño neuronal.Info
- Publication number
- MX9701333A MX9701333A MX9701333A MX9701333A MX9701333A MX 9701333 A MX9701333 A MX 9701333A MX 9701333 A MX9701333 A MX 9701333A MX 9701333 A MX9701333 A MX 9701333A MX 9701333 A MX9701333 A MX 9701333A
- Authority
- MX
- Mexico
- Prior art keywords
- neuronal damage
- methods
- inhibiting neuronal
- inhibiting
- hexamethyleneimino
- Prior art date
Links
- 230000002401 inhibitory effect Effects 0.000 title abstract 2
- 230000003961 neuronal insult Effects 0.000 title abstract 2
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Natural products C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 208000013016 Hypoglycemia Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- -1 hexamethyleneimino Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 230000002218 hypoglycaemic effect Effects 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 abstract 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/293,852 US5512296A (en) | 1994-08-22 | 1994-08-22 | Methods for inhibiting neuronal damage |
| PCT/US1995/010617 WO1996005811A1 (en) | 1994-08-22 | 1995-08-21 | Methods for inhibiting neuronal damage |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX9701333A true MX9701333A (es) | 1997-05-31 |
Family
ID=23130862
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX9701333A MX9701333A (es) | 1994-08-22 | 1995-08-21 | Metodos para inhibir el daño neuronal. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US5512296A (OSRAM) |
| EP (1) | EP0769937A4 (OSRAM) |
| JP (1) | JPH10504577A (OSRAM) |
| AU (1) | AU3369695A (OSRAM) |
| CA (1) | CA2198015A1 (OSRAM) |
| IL (1) | IL115020A0 (OSRAM) |
| MX (1) | MX9701333A (OSRAM) |
| TW (1) | TW296344B (OSRAM) |
| WO (1) | WO1996005811A1 (OSRAM) |
| ZA (1) | ZA956992B (OSRAM) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6417198B1 (en) | 1993-12-21 | 2002-07-09 | Eli Lilly And Company | Methods of inhibiting CNS problems in post-menopausal women |
| ZA982877B (en) * | 1997-04-09 | 1999-10-04 | Lilly Co Eli | Treatment of central nervous system disorders with selective estrogen receptor modulators. |
| US5990129A (en) * | 1997-09-23 | 1999-11-23 | Eli Lilly And Company | Methods for regulating trkA expression |
| US6288108B1 (en) | 1998-06-16 | 2001-09-11 | Eli Lilly And Company | Methods for increasing levels of acetylcholine |
| JP2002518329A (ja) | 1998-06-16 | 2002-06-25 | イーライ・リリー・アンド・カンパニー | アセチルコリンレベルを増加させる方法 |
| CZ20013912A3 (cs) | 1999-05-04 | 2002-05-15 | Strakan Limited | Androgen glykosid, sloučenina, testosteron-ß-D-glukosid, 5 alfa-Dihydrotestosteron- 17ß-D-glukosid, farmaceutický prostředek a pouľití sloučeniny |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4133814A (en) * | 1975-10-28 | 1979-01-09 | Eli Lilly And Company | 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents |
| US4380635A (en) * | 1981-04-03 | 1983-04-19 | Eli Lilly And Company | Synthesis of acylated benzothiophenes |
| US4418068A (en) * | 1981-04-03 | 1983-11-29 | Eli Lilly And Company | Antiestrogenic and antiandrugenic benzothiophenes |
| US5075321A (en) * | 1987-03-24 | 1991-12-24 | University Of Pennsylvania | Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes |
| US5395842A (en) * | 1988-10-31 | 1995-03-07 | Endorecherche Inc. | Anti-estrogenic compounds and compositions |
| JP3157882B2 (ja) * | 1991-11-15 | 2001-04-16 | 帝国臓器製薬株式会社 | 新規なベンゾチオフエン誘導体 |
| TW366342B (en) * | 1992-07-28 | 1999-08-11 | Lilly Co Eli | The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss |
| US5534526A (en) * | 1993-12-21 | 1996-07-09 | Eli Lilly And Company | Methods for inhibiting vasomotor symptoms and attending psychological disturbances surrounding post-menopausal syndrome |
| US6417198B1 (en) * | 1993-12-21 | 2002-07-09 | Eli Lilly And Company | Methods of inhibiting CNS problems in post-menopausal women |
-
1994
- 1994-08-22 US US08/293,852 patent/US5512296A/en not_active Expired - Fee Related
-
1995
- 1995-08-21 MX MX9701333A patent/MX9701333A/es unknown
- 1995-08-21 TW TW084108704A patent/TW296344B/zh active
- 1995-08-21 EP EP95930237A patent/EP0769937A4/en not_active Withdrawn
- 1995-08-21 IL IL11502095A patent/IL115020A0/xx unknown
- 1995-08-21 CA CA002198015A patent/CA2198015A1/en not_active Abandoned
- 1995-08-21 WO PCT/US1995/010617 patent/WO1996005811A1/en not_active Ceased
- 1995-08-21 JP JP8508250A patent/JPH10504577A/ja not_active Withdrawn
- 1995-08-21 AU AU33696/95A patent/AU3369695A/en not_active Abandoned
- 1995-08-21 ZA ZA9506992A patent/ZA956992B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL115020A0 (en) | 1995-12-08 |
| TW296344B (OSRAM) | 1997-01-21 |
| ZA956992B (en) | 1997-02-21 |
| JPH10504577A (ja) | 1998-05-06 |
| AU3369695A (en) | 1996-03-14 |
| US5512296A (en) | 1996-04-30 |
| CA2198015A1 (en) | 1996-02-29 |
| WO1996005811A1 (en) | 1996-02-29 |
| EP0769937A4 (en) | 1999-08-11 |
| EP0769937A1 (en) | 1997-05-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX9701325A (es) | Metodos para inhibir la mucositis ulcerativa. | |
| MX9701329A (es) | Metodos para la inhibicion de la replicacion viral. | |
| AU7578794A (en) | Methods for inhibiting endometriosis | |
| MX9701360A (es) | Metodos para la inhibicion de la desmielinizacion y las enfermedades de la dismielinizacion. | |
| DK0651999T3 (da) | Fremgangsmåder til inhibering af livmoderfibrose | |
| AU8154194A (en) | Method for increasing libido in post-menopausal women | |
| GR3035864T3 (en) | Methods for inhibiting cartilage degradation. | |
| AU8156294A (en) | Methods of inhibiting CNS problems in post-menopausal women | |
| MX9709466A (es) | Medicamento para inhibir el melanoma. | |
| MY113406A (en) | Methods of inhibiting physiological conditions associated with an excess of bradykinin | |
| ZA956988B (en) | Methods of inhibiting primary endometrial hyperplasia. | |
| MX9701328A (es) | Metodos de reduccion de la cicatrizacion en la curacion de heridas. | |
| MX9706072A (es) | Metodos de inhibicion de la adhesion celula-celula. | |
| MX9709536A (es) | Metodo para reducir el factor de transcripcion bef-1. | |
| MX9705697A (es) | Metodos para reducir los niveles de calcio del suero. | |
| MX9709651A (es) | Metodos para modulacion del factor de transcripcion nf-kb. | |
| MX9806036A (es) | Compuestos para inhibir tumores en el colon. |